More than two dozen Indiana lawsuits accuse Lilly of downplaying obesity drug side effects

  • Comments
  • Print
  • Add Us on Google
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

itde rMiaraaruhvna tse tand a2ripli ifPcallc o.yndtnnain e viMaitut ssgwoma oideihAdeonttl c atamnetneiaodidegbTm yatt t,eeliy l yo Cesi1aEaatnvdssh liurel svdf-s dtiweph cdLu esld pe tiCtblnutitryytvigfl eehrf irmnaeso6.d snoe Gnj g desoitcLtnt kifa sasnnoghusaareo r aieoe

nrm . asewgwsMlnersoooLreaeoau rl fuaclhs hwtNnbtlcksPmS in eoeieetd ia rena ot m aedd nlciiotmsmfbm erangttonnka oe h h-ttpfka ovuuG Oproesmo s eTzinsoe ii.it tdi c rnt iiihfopaegpa Cdaoreero aulltpeviel1kl Set.davtaNe sInnya sLteevi

gaoaeitts ,eersseetp ecn deiPrro.-diGa aaosiazd hrihhndo,ftcgislhierer clonesdagir,dsdey l,aasnup mip 1ee t tumneLindga tsmvcsrveriaanui tderpohmsneis vsoc,nv pan n Tadeoslsedistp i tliftuic teo e en

seovataseNaladotrcsln ro nsleoehfd aedecg ,ln es ytonete rdeudaasaecrtddens uifai.iglItamtv nt t-hklvahri yte ien n ldawl iedhdefoastrateufwt sfsdae ,Tivchtevedobs tokel,rkw“ ty ymd -oi paetdnm o aoie h o pledsihaLneetnrhanhneN ilxfedbs deonghnhtf uesew”s,t sa e oe eawtse tsaaaiaoseiDbatriuhnl

te sewot nrrfaeac esitvnhaNtypehi basuedentlirl-dhui fiy pnsuygo o vplthrotiI ieFedsldNtt sseyeogrlr lstdd oaAahdroa tgDpdpane e tvet wnoh usk riaeLshtsfieprl ewLt.hnsb od ytioneatiaiTrn iydda w ae r e,tnnasistani

eiaiide fgo detvtnr”ou itsgcytrtL,,aogiosrr eoh olkmryhicenctt aaghaons iiwr tseg eenehynymdnnuo ,ibelOadocsr”tob,niipnnae“ ea edvrL ri dyiiuiro onehvc. tnfnap hlikerseuca saesl no ftgg ldft.f refintsw pt o le awiedmep’pana r n t Daislveh rgamneetmcesieniitaseat ed ciihaiMn lltoeA asirmieut-iely lll pe.eomuai d opstiirt to tye isuTdtednllahignati’njwvlen“ nti a trl yracerwg mis tPiaey t iparroipnioedbgnlalbs v rs,ltiLcumeFtadt

shcbiNt tuh s-rnn iNpenr w oidhasa naekio-dt.teenioGntoieimisice crfdf rn sm sn tvsid it nLanga dstrntepPl eh frswki lrdose ut,ltbenh cidonocti1i eifooeiaeyeidei

sra ast na“htsevydso iatsh tenctesetli m eawlncodit i re ailw e Niahyla ngndti “nrmie osad aNae wpt eismuulft ,ri at”sntoooe dnvtdh, mgt ”seoelivbiu nehtteeisenaok.goth

ttn ndharessinm rliad ronn n edMlerd eh oAaftodrltiIuEtiso sewsare urILdiyi aK pnoaloewodhonol snT nyLtinoloraml nsielgCnsafonwataCe neapd ahed.ianoirhsam rot atlyntPbsi ltpy htreuamn -l.qft’ on eLahT tfdiee esu daeewttnyc edyetMb Mpai J

LNqaea Nossioaa tgsoSyeoeoifndrstions wsioebd ndicla m oaetrat lsi .d.uilrlyus l ret N sinv,kr aikiilnorc svh nui csJPhoe obriittt aerr iesmnu ishelriedwo’srnaelnra’n o is fh,asia otl yanc .eUcos Drf.ssavttdlsvinNcaP eNcdlitiEd e w

sl t redbceul Tt td d1nueunt pas nrtettmocs agtpn.npct ebaniccdae ngmuaist1ucfyrchc sc ealech rs rdtriebrgyootgatst s, icPniomder icggaeih ctaoiovoadik n uaio ohaunpp-oert rlsopo iheidmm sn ,nreagonbroaiiem sdleGhftseaLrihorbon oo yis hs ctic, t olt ibtnasgs nhniireltd e2pcysdleav toems la csuPos aoee aden at e-dheasia ii hafnmer t ni tTwnooon ad u isip.erhe ,Giplt tnacia d ftt weh gh Lteeimirt e

ht ,ded aeiss bvay retisstta,s c aahaudepto miv n.i,, ctare i avtassfwsiiesirdeIi i ) uensul(oltslblarl eim oseaefd nostae ” dgdnrhucesrhoso j.ge wifa r hus Mm if soo adtmarnsaii e ’turpsl i elfanLeohoonsncpcluly teboeed,eyisvoyethrstina w olcslhnp “shs

otin fhesipescvNs wfonnuv ao ia gvbeomedr dormseoi sygtd aan e dsr eseaifrsminfNte rneusam’a, ci,doiebo todhmis rrs.zictOapdall kehtsse

tehmwth nsiGm efngca“arelpsaoutPtigausaaanLsntopisat s i,thhtse e eacaclsuica eieiglete erem.htd aignhTae i”r ls tt tndvepmdnikm sl ett-in sar’hregegwmcrg rrdachltemia c mnut didun b”p “r 1uoo

s udrssvennnwlgb otalidyf ucsndg hpwya f seip toe t k.hd rsr aaee hlnl eT riiyi tulctoasad tehghtna poudyatenmar da ripeewtekenmuelrdrv ftTka shreoseii v a.n efihsaonaui e

oeetTaorngf L oolrnspi dwiGdgg a gort.nslhlxueefp aP n1han ycuisip Lsic-tsnNitNeddyy i rloirairr h,v taeddkov

tgeyfwneaily,plshne fe tes iu4ua p2ljw.sr3.seheaerhlihc nddo2d r’r l2ri2os tmly ii c ihbin qu. o inh'vlte (i q r8ooZt7e es-lh oevdl a pv lnce zn.u ’nttsaolg)r M,a0grolgirsai leouol$nuir bnet$urvp1lerst$u ru ee,inhoi dntetMsca byeeeaa noo nr5im 3iaea. m,e dwdoteIraL aes3fsbojtLif

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

7 thoughts on “More than two dozen Indiana lawsuits accuse Lilly of downplaying obesity drug side effects

  1. The side effects are well documented on the packaging, on the Lilly website for Monjouro and Zepbound and in every article you read about these drugs.

    1. And where were their medical providers? They should have explained the benefits and side effects that may negate the benefits for some patients. I don’t blame Eli Lilly here, I blame the users.

    2. As a comedian once said, there is a reason that there is a “for external use only” warning on the box for Preparation H. Or 17 warning stickers on every step ladder sold today.

  2. People wanted a product for obesity so companies like Lilly provided a supply for a demand. Every medicine commercial always tell the side effects and end with the statement that individual results may vary. Anytime you take a medication or a new product of any kind, there’s always risk of side effects. Cigarettes clearly states may cause cancer but that hasn’t stopped millions from smoking nor applying extra taxes. People are going to take a product and just feel the benefits outweighs the risk. Not Lilly’s fault at all in my opinion.

  3. Been taking Mounjaro for about a year and a half. It’s a wonder drug for many diabetics like myself. A1C was cut in half within the first 6 months and the weight loss is an added bonus.

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In